Diphtheria is a forgotten disease that, despite advances in medicine and vaccination, is increasingly re-emerging in various parts of the world, including developed countries. It is caused by the bacterium Corynebacterium diphtheriae, which produces diphtheria toxin responsible for the severe course of the disease. However, only toxigenic strains-those carrying the tox gene, are capable of producing this toxin. The majority of C. diphtheriae strains isolated in Poland do not contain this gene, which is why infections caused by them are usually milder. Depending on the site of infection, symptoms most commonly involve the upper respiratory tract, with the hallmark sign being the presence of pseudomembranes. Rapid diagnosis and accurate confirmation of the pathogen are essential not only for implementing proper preventive measures, but above all for initiating timely treatment and preventing serious organ complications. Vaccination plays a key role in diphtheria prevention, offering effective protection against infection and transmission. Despite the availability of both preventive and therapeutic measures, diphtheria is becoming an increasing threat in countries with low vaccination rates. The growing number of cases particularly among children, highlights the urgent need for education and improvement in both prevention and treatment strategies.
Background: Central Sensitization Syndrome (CSS) is increasingly recognized as a critical contributor to chronic pelvic pain in women with pelvic organ prolapse (POP). The coexistence of mechanical dysfunction and altered central pain modulation complicates diagnosis and management, requiring a multidimensional approach that integrates neurobiological, hormonal, and psychosocial perspectives. Objective: To analyze the mechanisms of central sensitization in women with pelvic organ prolapse, review current diagnostic methods, and evaluate therapeutic strategies based on recent scientific evidence. Methods: A narrative evidence-based review was conducted using PubMed, Scopus, and Web of Science databases for publications from 2015 to 2024. Studies addressing the mechanisms, diagnosis, and treatment of central sensitization in pelvic organ prolapse or related chronic pelvic pain syndromes were included. Data were synthesized qualitatively with critical appraisal of methodological rigor and clinical relevance. Results: The literature confirms that chronic pain in women with POP often results from maladaptive neuroplasticity and central hypersensitivity rather than from anatomical defects alone. Estrogen deficiency, neuroinflammation, and prolonged nociceptive stimulation act synergistically to maintain central excitability. Effective diagnostics require a combination of clinical evaluation, validated questionnaires, quantitative sensory testing, and neuroimaging. Treatment should follow a biopsychosocial model that integrates pharmacotherapy (gabapentinoids, SNRIs, anti-inflammatory agents), physiotherapy, and psychological interventions such as cognitive-behavioral therapy. Noninvasive neuromodulation and molecular therapies targeting NMDA and TRPV1 receptors show emerging promise. Conclusions: Central sensitization represents a pivotal but underdiagnosed mechanism in the pathophysiology of pelvic organ prolapse–related pain. Early identification of CSS features and implementation of individualized multimodal therapy improve pain control, functional outcomes, and quality of life. Multidisciplinary collaboration remains essential for optimizing diagnosis and treatment in this complex patient population.
23 December 2025 in International Journal of Innovative Technologies in Social Science
Migraine is one of the most common and burdensome neurological disorders, affecting approximately 15% of the global population. This paper provides a review of the current knowledge on the epidemiology, pathophysiology, and treatment of chronic migraine, with particular emphasis on the role of botulinum toxin type A. It presents the key biological mechanisms underlying migraine, including activation of the trigeminovascular system, the significance of neuropeptides such as CGRP, and the involvement of cortical spreading depression (CSD) in migraine with aura. Modern pathophysiological concepts related to autonomic and metabolic system dysfunction are also discussed. Based on an analysis of clinical trials and meta-analyses, the efficacy and safety of onabotulinumtoxinA therapy according to the PREEMPT protocol are evaluated, as well as its place in current therapeutic guidelines. The paper concludes with a discussion of future research perspectives, including the potential for synergy with biological therapies (anti-CGRP), optimization of treatment regimens, and the use of biomarkers.
Disorders of gut-brain interaction (DGBI) such as irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO) pose a clinical challenge because of their complex pathophysiology and diagnostic difficulties. This study aimed to analyze modern diagnostic methods and therapeutic strategies, focusing on emerging technologies and personalized approaches. IBS and SIBO are complex gastrointestinal disorders involving gut dysbiosis, motility disturbances, and interactions within the gut-brain axis. In IBS, dietary and psychological factors are key to making dietary interventions, such as a low FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet, and psychological therapies are particularly effective. SIBO treatment primarily relies on antibiotic therapy, although frequent relapses have driven the search for alternative approaches, including microbiota modulation. Increasing attention has been given to advanced technologies such as metabolomic analysis, microbiome profiling, and fecal microbiota transplantation, which may enhance treatment efficacy and enable a more personalized therapeutic approach. Advancements in IBS and SIBO diagnostics and treatment have allowed for a more precise therapeutic approach. Further research is required to assess the efficacy of these novel methods. Understanding gut-brain interactions and the role of gut microbiota in the pathogenesis of these disorders is crucial for developing more effective and sustainable therapeutic strategies.